Remifentanil Versus Alfentanil: Comparative Pharmacokinetics and Pharmacodynamics in Healthy Adult Male Volunteers

Background Remifentanil is an esterase-metabolized opioid with a rapid clearance. The aim of this study was to contrast the pharmacokinetics and pharmacodynamics of remifentanil and alfentanil in healthy, adult male volunteers. Methods Ten volunteers received infusions of remifentanil and alfentanil on separate study sessions using a randomized, open-label crossover design. Arterial blood samples were analyzed to determine drug blood concentrations. The electroencephalogram was employed as the measure of drug effect. The pharmacokinetics were characterized using a moment analysis, a nonlinear mixed effects model (NONMEM) population analysis, and context-sensitive half-time computer simulations. After processing the raw electroencephalogram to obtain the spectral edge parameter, the pharmacodynamics were characterized using an effect compartment, inhibitory maximum effect model. Results Pharmacokinetically, the two drugs are similar in terms of steady-state distribution volume (VDss), but remifentanil's central clearance (CLc) is substantially greater. The NONMEM analysis population pharmacokinetic parameters for remifentanil include a CLc of 2.9 l *symbol* min sup -1, a VDss of 21.81, and a terminal half-life of 35.1 min. Corresponding NONMEM parameters for alfentanil are 0.36 l *symbol* min sup -1, 34.11, and 94.5 min. Pharmacodynamically, the drugs are similar in terms of the time required for equilibration between blood and the effect-site concentrations, as evidenced by a T12 Ke0 for remifentanil of 1.6 min and 0.96 min for alfentanil. However, remifentanil is 19 times more potent than alfentanil, with an effective concentration for 50% maximal effect of 19.9 ng *symbol* ml sup -1 versus 375.9 ng *symbol* ml sup -1 for alfentanil. Conclusions Compared to alfentanil, the high clearance of remifentanil, combined with its small steady-state distribution volume, results in a rapid decline in blood concentration after termination of an infusion. With the exception of remifentanil's nearly 20-times greater potency (30-times if alfentanil partitioning between whole blood and plasma is considered), the drugs are pharmacodynamically similar.

[1]  P. Glass,et al.  Preliminary Pharmacokinetics and Pharmacodynamics of an Ultra‐Short‐Acting Opioid: Remifentanil (GI87084B) , 1993, Anesthesia and analgesia.

[2]  I. M. Davis,et al.  Determination of remifentanil in human blood by liquid-liquid extraction and capillary GC-HRMS-SIM using a deuterated internal standard. , 1994, Journal of pharmaceutical and biomedical analysis.

[3]  M. K. James,et al.  Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues. , 1991, The Journal of pharmacology and experimental therapeutics.

[4]  D R Stanski,et al.  Pharmacodynamic modeling of anesthetic EEG drug effects. , 1992, Annual review of pharmacology and toxicology.

[5]  J. Heykants,et al.  Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. , 1982, Archives internationales de pharmacodynamie et de therapie.

[6]  S L Shafer,et al.  Pharmacokinetics, pharmacodynamics, and rational opioid selection. , 1991, Anesthesiology.

[7]  James C. Scott,et al.  Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. , 1991, Anesthesiology.

[8]  D R Stanski,et al.  Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. , 1987, The Journal of pharmacology and experimental therapeutics.

[9]  M. K. James,et al.  Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. , 1991, Journal of medicinal chemistry.

[10]  S. Shafer.  More on: improving the clinical utility of anesthetic drug pharmacokinetics. , 1992, Anesthesiology.

[11]  D R Stanski,et al.  Understanding pharmacokinetics and pharmacodynamics through computer stimulation: I. The comparative clinical profiles of fentanyl and alfentanil. , 1990, Anesthesiology.

[12]  J. Reves,et al.  Effect site equilibration time is a determinant of induction dose requirement. , 1993, Anesthesia and analgesia.

[13]  C A Shanks,et al.  Minimal compartmental model of circulatory mixing of indocyanine green. , 1992, The American journal of physiology.

[14]  P. Sebel,et al.  The Pharmacokinetics of Alfentanil (R39209): A New Opioid Analgesic , 1982, Anesthesiology.

[15]  D R Stanski,et al.  EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. , 1985, Anesthesiology.

[16]  H. Shapiro,et al.  Automated EEG processing for intraoperative monitoring: a comparison of techniques. , 1980, Anesthesiology.

[17]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm , 1987, Comput. Appl. Biosci..

[18]  S. Shafer,et al.  Pharmacokinetic Parameters Relevant to Recovery from Opioids , 1994, Anesthesiology.

[19]  David J. Hermann,et al.  The Pharmacokinetics of the New Short‐acting Opioid Remifentanil (GI87084B) in Healthy Adult Male Volunteers , 1993, Anesthesiology.

[20]  M. A. Hughes,et al.  Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. , 1992, Anesthesiology.

[21]  K T Muir,et al.  Pharmacokinetics of Remifentanil (GI87084B) and Its Major Metabolite (GI90291) in Patients Undergoing Elective Inpatient Surgery , 1993, Anesthesiology.

[22]  A Sibbald,et al.  A pharmacodynamic model for pancuronium. , 1978, British journal of anaesthesia.